Sanofi (SNY) Income from Continuing Operations (2009 - 2026)
Sanofi (SNY) posted Income from Continuing Operations of 17108804128.44 for Q2 2026, up 14.58% sequentially from 14931690021.08 in Q1 2026, and up 21.97% YoY from 14027244453.59 in Q2 2025.
Sanofi (SNY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Sanofi has reported Income from Continuing Operations for 18 years, with the latest figure at 17108804128.44 in Q2 2026.
- Quarterly Income from Continuing Operations rose 21.97% year-over-year to 17108804128.44 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 92241628000.43 (up 88.39% YoY) and the FY2025 annual result came in at 5973871317.43, up 66.88% from the prior year.
- Income from Continuing Operations rose to 17108804128.44 in Q2 2026 per SNY's latest filing, from 14931690021.08 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 50289431345.79 in Q4 2023 and troughed at 6152972314.14 in Q4 2024.
- A 5-year average of 18789437046.11 and a median of 13999047358.5 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 2253.86% in 2022, then plunged 87.76% in 2024.
- Over 5 years, Income from Continuing Operations stood at 41559776425.37 in 2022, then grew by 21.01% to 50289431345.79 in 2023, then slumped by 87.76% to 6152972314.14 in 2024, then soared by 127.06% to 13970850263.41 in 2025, then increased by 22.46% to 17108804128.44 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 17108804128.44, 14931690021.08, and 13970850263.41 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.11 Bn |
| Mar 31, 2026 | 14.93 Bn |
| Dec 31, 2025 | 13.97 Bn |
| Sep 30, 2025 | 46.23 Bn |
| Jun 30, 2025 | 14.03 Bn |
| Mar 31, 2025 | 13.09 Bn |
| Dec 31, 2024 | 6.15 Bn |
| Sep 30, 2024 | 15.69 Bn |
| Jun 30, 2024 | 11.27 Bn |
| Mar 31, 2024 | 11.83 Bn |
| Dec 31, 2023 | 50.29 Bn |
| Sep 30, 2023 | 15.22 Bn |
| Jun 30, 2023 | 13.17 Bn |
| Mar 31, 2023 | 13.50 Bn |
| Dec 31, 2022 | 41.56 Bn |
| Sep 30, 2022 | 14.51 Bn |
| Jun 30, 2022 | 12.79 Bn |
| Mar 31, 2022 | 12.86 Bn |
| Dec 31, 2021 | 1.77 Bn |
| Sep 30, 2021 | 14.14 Bn |